ReviewCancers2021

HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.

Kimio YonesakaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.